Ixekizumab Superior to Etanercept in Psoriasis

Save

The UNCOVER-2 and UNCOVER-3 trials were presented at the American Academy of Dermatology (AAD) Annual Meeting taking this week in Washington, D.C.

The Week in Review - 4 March 2016

Save

Highlights from this week on RheumNow:

TNF Inhibition and Heart Failure

Save

Clinicians often face the issue of using a TNF inhibitor (TNFi) in patients with heart failure or cardiac disease. Here are the facts and data necessary to make a cogent decision to use or avoid TNFi.

Less Treatment, Responses and Safety in Elder-Onset Rheumatoid Arthritis

Save

A recent review compared elderly-onset rheumatoid arthritis (EORA) to those with younger-onset rheumatoid arthritis (YORA) to assess treatment responses and safety issues with biologics and DMARDS. EORA is generally defined as the onset of rheumatoid arthritis after age 60 years.

Curbside Consults - February 2016

Save

The following is a collection of cases presented to me by rheumatology colleagues. Each has a challenging therapeutic or safety issue. Answers are based on experience with references from literature and guidelines.

Challenges of Dermatomyositis Progress

Save

In the current issue of Lancet, Pierre Miossec discusses the challenges of studying and managing juvenile dermatomyositis and, specifically, the

Hidradenitis Suppurativa Increases Cardiovascular Event Risk

Save

Hidradenitis suppurativa (HS) is a chronic inflammatory disease affecting exocrine glands with painful abscesses in intertriginous areas.

RWCS 2016 – Periodic Fever and Macrophage Activation Syndrome + Pregnancy in IBD

Save

Pregnancy and Immune Modulating Therapies

RWCS 2016 - Updates in AS, PsA and Lupus

Save

Update on Ankylosing Spondylitis and Spondyloarthritis

RWCS 2016 – OA/OP, Gout, Sarcoid & JIA Reviewed

Save

Recent Developments in Osteoarthritis, Osteoporosis and Gout

RWCS 2016 – Rheumatoid Review, Psoriatic Arthritis and Medical Marijuana

Save

The Rheumatology Winter Clinical Symposia launched its 9th annual conference yesterday in Maui. Highlights of this meeting will be covered by RheumNow from Wednesday 2/10 till Saturday 2/13.

Rheumatoid Arthritis Year in Review

Rheumatoid Modern Management is Better but More Costly

Save

The mantra of rheumatologists worldwide is to treat rheumatoid arthritis (RA) earlier and more aggressively. While referral of early RA patients has improved, there is little data demonstrating that more aggressive treatment works or is cost effective.

FDA Advisory Arthritis Committee Votes to Approve the CT-P13 (infliximab) Biosimilar

Save

On Tuesday February 9th Celltrion presented its biosimilar developmental data to the FDA as they sought approval for their CT-P13 (called Inflectra), a biosimilar of infliximab (Remicade).

FDA Reviews Celltrion's Remicade Biosimilar Today

Save

The arthritis advisory committee of the Food and Drug Administration (FDA) is scheduled to meet today, February 9th to review the efficacy and safety of Celltrion's biosimilar form of infliximab (Remicade) that is currently marketed in other countries.

Rheumatoid Arthritis, TNF inhibitors and the Risk of Skin Cancer

Save

Rheumatoid arthritis (RA) patients are said to have a neutral risk for neoplasia, but this is because they have a lower risk of colon cancer and breast cancer but a higher risk of lung cancer, lymphoma and skin cancers.

Biosimilar of Remicade Works in Ankylosing Spondylitis

Save

CT-P13, a biosimilar of infliximab (Remicade), demonstrated comparable and durable efficacy in the treatment of ankylosing spondylitis (AS), a multinational study found.

NIH-Funded Trials Down, While Industry Trials Increase

Save

(Reuters Health) – Every year since 2006 in the U.S., the amount of new medical research in humans funded by the National Institutes of Health (NIH) has gone down, while the number of industry-funded trials has gone up, a new study shows. 

Updated RA Treat-to-Target International Recommendations

Save

In 2010, Smolen and a group of international rheumatologists developed a series of recommendations addressing the concept of treat-to-target (T2T) in the management of rheumatoid arthritis (RA).

Biosimilar Reports - January 2016

Save

Biosimilars are the fastest developing product line within the pharmaceutical industry. There is unanimous worldwide interest in the continued use of biologics for immune mediated disorders.

Risk of Multiple Sclerosis with TNF Inhibitor Therapy

Save

Researchers from the DANBIO registry have linked their registry of 30,033 arthritis patients with the Danish Multiple Sclerosis Registry (DMSR) to identify all new multiple sclerosis cases occuring in arthritis patients and those receiving TNF inhibitors (TNFi).